{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:41:42Z","timestamp":1790505702799,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T00:00:00Z","timestamp":1613865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T00:00:00Z","timestamp":1613865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7204252"],"award-info":[{"award-number":["7204252"]}]},{"name":"Beijing Hospitals Authority Youth Programme","award":["QML20200603"],"award-info":[{"award-number":["QML20200603"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Epigenetic regulations essentially participate in the development of cardiomyocyte hypertrophy. PHD finger protein 19 (PHF19) is a polycomb protein that controls H3K36me3 and H3K27me3. However, the roles of PHF19 in cardiac hypertrophy remain unknown. Here in this work, we observed that PHF19 promoted cardiac hypertrophy via epigenetically targeting SIRT2. In angiotensin II (Ang II)-induced cardiomyocyte hypertrophy, adenovirus-mediated knockdown of<jats:italic>Phf19<\/jats:italic>reduced the increase in cardiomyocyte size, repressed the expression of hypertrophic marker genes<jats:italic>Anp<\/jats:italic>and<jats:italic>Bnp<\/jats:italic>, as well as inhibited protein synthesis. By contrast,<jats:italic>Phf19<\/jats:italic>overexpression promoted Ang II-induced cardiomyocyte hypertrophy in vitro. We also knocked down<jats:italic>Phf19<\/jats:italic>expression in mouse hearts in vivo. The results demonstrated that<jats:italic>Phf19<\/jats:italic>knockdown reduced Ang II-induced decline in cardiac fraction shortening and ejection fraction.<jats:italic>Phf19<\/jats:italic>knockdown also inhibited Ang II-mediated increase in heart weight, reduced cardiomyocyte size, and repressed the expression of hypertrophic marker genes in mouse hearts. Further mechanism studies showed that PHF19 suppressed the expression of SIRT2, which contributed to the function of PHF19 during cardiomyocyte hypertrophy. PHF19 bound the promoter of SIRT2 and regulated the balance between H3K27me3 and H3K36me3 to repress the expression of SIRT2 in vitro and in vivo. In human hypertrophic hearts, the overexpression of PHF19 and downregulation of SIRT2 were observed. Of importance,<jats:italic>PHF19<\/jats:italic>expression was positively correlated with hypertrophic marker genes<jats:italic>ANP<\/jats:italic>and<jats:italic>BNP<\/jats:italic>but negatively correlated with<jats:italic>SIRT2<\/jats:italic>in human hypertrophic hearts. Therefore, our findings demonstrated that PHF19 promoted the development of cardiac hypertrophy via epigenetically regulating SIRT2.<\/jats:p>","DOI":"10.1007\/s12012-021-09639-0","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T05:05:59Z","timestamp":1613883959000},"page":"451-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["PHD Finger Protein 19 Promotes Cardiac Hypertrophy via Epigenetically Regulating SIRT2"],"prefix":"10.1007","volume":"21","author":[{"given":"Wei","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4796-7393","authenticated-orcid":false,"given":"Zhizhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,21]]},"reference":[{"key":"9639_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-981-13-1117-8_4","volume":"1086","author":"YN Ding","year":"2018","unstructured":"Ding, Y. N., Tang, X., Chen, H. Z., & Liu, D. P. (2018). Epigenetic regulation of vascular aging and age-related vascular diseases. Advances in Experimental Medicine and Biology, 1086, 55\u201375.","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"9639_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3389\/fendo.2020.00462","volume":"11","author":"X-F Chen","year":"2020","unstructured":"Chen, X.-F., Yan, L.-J., Lecube, A., & Tang, X. (2020). Editorial: Diabetes and obesity effects on lung function. Frontiers in Endocrinology (Lausanne), 11, 462.","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"issue":"11","key":"9639_CR3","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1161\/CIRCRESAHA.117.311082","volume":"120","author":"JM Bravo-San Pedro","year":"2017","unstructured":"Bravo-San Pedro, J. M., Kroemer, G., & Galluzzi, L. (2017). Autophagy and mitophagy in cardiovascular disease. Circulation Research, 120(11), 1812\u20131824.","journal-title":"Circulation Research"},{"key":"9639_CR4","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani, A., Rawshani, A., Franz\u00e9n, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., et al. (2017). Mortality and cardiovascular disease in type 1 and type 2 diabetes. New England Journal of Medicine, 376, 1407\u20131418.","journal-title":"New England Journal of Medicine"},{"key":"9639_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"M Nakamura","year":"2018","unstructured":"Nakamura, M., & Sadoshima, J. (2018). Mechanisms of physiological and pathological cardiac hypertrophy. Nature Reviews Cardiology, 15, 387\u2013407.","journal-title":"Nature Reviews Cardiology"},{"key":"9639_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1042\/CS20200128","volume":"134","author":"X-F Chen","year":"2020","unstructured":"Chen, X.-F., Chen, X., & Tang, X. (2020). Short-chain fatty acid, acylation and cardiovascular diseases. Clinical Science, 134, 657\u2013676.","journal-title":"Clinical Science"},{"key":"9639_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fendo.2020.00280","volume":"11","author":"X Tang","year":"2020","unstructured":"Tang, X., Li, P.-H., & Chen, H.-Z. (2020). Cardiomyocyte senescence and cellular communications within myocardial microenvironment. Frontiers in Endocrinology (Lausanne), 11, 280.","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"key":"9639_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","volume":"97","author":"I Shimizu","year":"2016","unstructured":"Shimizu, I., & Minamino, T. (2016). Physiological and pathological cardiac hypertrophy. Journal of Molecular and Cellular Cardiology, 97, 245\u2013262.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"9639_CR9","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1172\/JCI46277","volume":"121","author":"Q-J Zhang","year":"2011","unstructured":"Zhang, Q.-J., Chen, H.-Z., Wang, L., Liu, D.-P., Hill, J. A., & Liu, Z.-P. (2011). The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. The Journal of Clinical Investigation, 121, 2447\u20132456.","journal-title":"The Journal of Clinical Investigation"},{"key":"9639_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fphys.2020.00539","volume":"11","author":"S Yu","year":"2020","unstructured":"Yu, S., Li, Y., Zhao, H., Wang, Q., & Chen, P. (2020). The histone demethylase JMJD1C regulates CAMKK2-AMPK signaling to participate in cardiac hypertrophy. Frontiers in Physiology, 11, 539.","journal-title":"Frontiers in Physiology"},{"key":"9639_CR11","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.1038\/s41467-018-07173-2","volume":"9","author":"Q-J Zhang","year":"2018","unstructured":"Zhang, Q.-J., Tran, T. A. T., Wang, M., Ranek, M. J., Kokkonen-Simon, K. M., Gao, J., et al. (2018). Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis. Nature Communications, 9, 5230.","journal-title":"Nature Communications"},{"key":"9639_CR12","doi-asserted-by":"publisher","first-page":"ra34","DOI":"10.1126\/scisignal.aad5736","volume":"9","author":"CR Morales","year":"2016","unstructured":"Morales, C. R., Li, D. L., Pedrozo, Z., May, H. I., Jiang, N., Kyrychenko, V., et al. (2016). Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression. Science Signaling, 9, ra34\u2013ra34.","journal-title":"Science Signaling"},{"key":"9639_CR13","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/nsmb.2449","volume":"19","author":"GL Brien","year":"2012","unstructured":"Brien, G. L., Gambero, G., O\u2019Connell, D. J., Jerman, E., Turner, S. A., Egan, C. M., et al. (2012). Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation. Nature Structural & Molecular Biology, 19, 1273\u20131281.","journal-title":"Nature Structural & Molecular Biology"},{"key":"9639_CR14","doi-asserted-by":"publisher","first-page":"eabb2745","DOI":"10.1126\/sciadv.abb2745","volume":"6","author":"P Viz\u00e1n","year":"2020","unstructured":"Viz\u00e1n, P., Guti\u00e9rrez, A., Espejo, I., Garc\u00eda-Montolio, M., Lange, M., Carretero, A., et al. (2020). The Polycomb-associated factor PHF19 controls hematopoietic stem cell state and differentiation. Science Advances, 6, eabb2745.","journal-title":"Science Advances"},{"key":"9639_CR15","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s41375-020-0742-z","volume":"34","author":"MJ Mason","year":"2020","unstructured":"Mason, M. J., Schinke, C., Eng, C. L. P., Towfic, F., Gruber, F., Dervan, A., et al. (2020). Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia, 34, 1866\u20131874.","journal-title":"Leukemia"},{"key":"9639_CR16","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1182\/blood.2019000578","volume":"134","author":"Z Ren","year":"2019","unstructured":"Ren, Z., Ahn, J. H., Liu, H., Tsai, Y.-H., Bhanu, N. V., Koss, B., et al. (2019). PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. Blood, 134, 1176\u20131189.","journal-title":"Blood"},{"key":"9639_CR17","doi-asserted-by":"publisher","first-page":"e51373","DOI":"10.7554\/eLife.51373","volume":"9","author":"P Jain","year":"2020","unstructured":"Jain, P., Ballare, C., Blanco, E., Vizan, P., & Di Croce, L. (2020). PHF19 mediated regulation of proliferation and invasiveness in prostate cancer cells. Elife, 9, e51373.","journal-title":"Elife"},{"key":"9639_CR18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3389\/fendo.2018.00748","volume":"9","author":"S Zhou","year":"2018","unstructured":"Zhou, S., Tang, X., & Chen, H. Z. (2018). Sirtuins and insulin resistance. Frontiers in Endocrinology. (Lausanne), 9, 748.","journal-title":"Frontiers in Endocrinology. (Lausanne)"},{"key":"9639_CR19","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.117.028728","volume":"136","author":"X Tang","year":"2017","unstructured":"Tang, X., Chen, X.-F., Wang, N.-Y., Wang, X.-M., Liang, S.-T., Zheng, W., et al. (2017). SIRT2 acts as a cardioprotective deacetylase in pathological cardiac hypertrophy. Circulation, 136, 2051\u20132067.","journal-title":"Circulation"},{"key":"9639_CR20","doi-asserted-by":"publisher","first-page":"e32952","DOI":"10.7554\/eLife.32952","volume":"7","author":"M Sarikhani","year":"2018","unstructured":"Sarikhani, M., Mishra, S., Maity, S., Kotyada, C., Wolfgeher, D., Gupta, M. P., et al. (2018). SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation. ELife, 7, e32952.","journal-title":"ELife"},{"key":"9639_CR21","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1074\/jbc.RA117.000915","volume":"293","author":"M Sarikhani","year":"2018","unstructured":"Sarikhani, M., Maity, S., Mishra, S., Jain, A., Tamta, A. K., Ravi, V., et al. (2018). SIRT2 deacetylase represses NFAT transcription factor to maintain cardiac homeostasis. Journal of Biological Chemistry, 293, 5281\u20135294.","journal-title":"Journal of Biological Chemistry"},{"key":"9639_CR22","doi-asserted-by":"crossref","first-page":"e016419","DOI":"10.1161\/JAHA.120.016419","volume":"9","author":"X Zhang","year":"2020","unstructured":"Zhang, X., Lei, F., Wang, X. M., Deng, K. Q., Ji, Y. X., Zhang, Y., et al. (2020). NULP1 alleviates cardiac hypertrophy by suppressing NFAT3 transcriptional activity. Journal of the American Heart Association, 9, e016419.","journal-title":"Journal of the American Heart Association"},{"key":"9639_CR23","doi-asserted-by":"publisher","first-page":"e97999","DOI":"10.1371\/journal.pone.0097999","volume":"9","author":"Y-Y Jia","year":"2014","unstructured":"Jia, Y.-Y., Lu, J., Huang, Y., Liu, G., Gao, P., Wan, Y.-Z., et al. (2014). The involvement of NFAT transcriptional activity suppression in SIRT1-mediated inhibition of COX-2 expression induced by PMA\/Ionomycin. PLoS ONE, 9, e97999.","journal-title":"PLoS ONE"},{"key":"9639_CR24","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1038\/ncomms6515","volume":"5","author":"G Mearini","year":"2014","unstructured":"Mearini, G., Stimpel, D., Geertz, B., Weinberger, F., Kr\u00e4mer, E., Schlossarek, S., et al. (2014). Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nature Communications, 5, 5515.","journal-title":"Nature Communications"},{"issue":"14","key":"9639_CR25","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1074\/jbc.RA119.010734","volume":"295","author":"X Han","year":"2020","unstructured":"Han, X., Chen, H., Gong, H., Tang, X., Huang, N., Xu, W., et al. (2020). Autolysosomal degradation of cytosolic chromatin fragments antagonizes oxidative stress\u2013induced senescence. Journal of Biological Chemistry., 295(14), 4451\u20134463.","journal-title":"Journal of Biological Chemistry."},{"key":"9639_CR26","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1042\/CS20160685","volume":"131","author":"X Tang","year":"2017","unstructured":"Tang, X., Chen, X.-F., Chen, H.-Z., & Liu, D.-P. (2017). Mitochondrial sirtuins in cardiometabolic diseases. Clinical Science, 131, 2063\u20132078.","journal-title":"Clinical Science"},{"key":"9639_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jcmm.13961","volume":"23","author":"X-L Zhou","year":"2019","unstructured":"Zhou, X.-L., Zhu, R.-R., Wu, X., Xu, H., Li, Y.-Y., Xu, Q.-R., et al. (2019). NSD2 promotes ventricular remodelling mediated by the regulation of H3K36me2. Journal of Cellular and Molecular Medicine, 23, 568\u2013575.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"9639_CR28","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/nsmb.2434","volume":"19","author":"C Ballar\u00e9","year":"2012","unstructured":"Ballar\u00e9, C., Lange, M., Lapinaite, A., Martin, G. M., Morey, L., Pascual, G., et al. (2012). Phf19 links methylated Lys36 of histone H3 to regulation of polycomb activity. Nature Structural & Molecular Biology, 19, 1257\u20131265.","journal-title":"Nature Structural & Molecular Biology"},{"key":"9639_CR29","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1038\/s41467-019-09882-8","volume":"10","author":"Y Ji","year":"2019","unstructured":"Ji, Y., Fioravanti, J., Zhu, W., Wang, H., Wu, T., Hu, J., et al. (2019). miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate. Nature Communications, 10, 2157.","journal-title":"Nature Communications"},{"key":"9639_CR30","first-page":"200","volume":"10","author":"F Ning","year":"2018","unstructured":"Ning, F., Wang, C., Niu, S., Xu, H., Xia, K., & Wang, N. (2018). Transcription factor Phf19 positively regulates germinal center reactions that underlies its role in rheumatoid arthritis. American Journal of Translational Research, 10, 200\u2013211.","journal-title":"American Journal of Translational Research"},{"key":"9639_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s11427-014-4687-1","volume":"57","author":"W Mu","year":"2014","unstructured":"Mu, W., Zhang, Q., Tang, X., Fu, W., Zheng, W., Lu, Y., et al. (2014). Overexpression of a dominant-negative mutant of SIRT1 in mouse heart causes cardiomyocyte apoptosis and early-onset heart failure. Science China Life Sciences, 57, 915\u2013924.","journal-title":"Science China Life Sciences"},{"key":"9639_CR32","doi-asserted-by":"publisher","first-page":"36576","DOI":"10.1038\/srep36576","volume":"6","author":"X Tang","year":"2016","unstructured":"Tang, X., Ma, H., Han, L., Zheng, W., Lu, Y. B., Chen, X. F., et al. (2016). SIRT1 deacetylates the cardiac transcription factor Nkx2.5 and inhibits its transcriptional activity. Scientific Reports, 6, 36576.","journal-title":"Scientific Reports"},{"key":"9639_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/eurheartj\/ehx493.P6486","volume":"38","author":"Y-X Luo","year":"2017","unstructured":"Luo, Y.-X., Tang, X., An, X.-Z., Xie, X.-M., Chen, X.-F., Zhao, X., et al. (2017). Sirt4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity. European Heart Journal, 38, 1389\u20131398.","journal-title":"European Heart Journal"},{"key":"9639_CR34","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1073\/pnas.1519858113","volume":"113","author":"S Sadhukhan","year":"2016","unstructured":"Sadhukhan, S., Liu, X., Ryu, D., Nelson, O. D., Stupinski, J. A., Li, Z., et al. (2016). Metabolomics-assisted proteomics identifies succinylation and SIRT5 as important regulators of cardiac function. Proceedings of the National Academy of Sciences, 113, 4320\u20134325.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"9639_CR35","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1038\/ncomms7656","volume":"6","author":"VB Pillai","year":"2015","unstructured":"Pillai, V. B., Samant, S., Sundaresan, N. R., Raghuraman, H., Kim, G., Bonner, M. Y., et al. (2015). Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nature Communications, 6, 6656.","journal-title":"Nature Communications"},{"key":"9639_CR36","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/nm.2961","volume":"18","author":"NR Sundaresan","year":"2012","unstructured":"Sundaresan, N. R., Vasudevan, P., Zhong, L., Kim, G., Samant, S., Parekh, V., et al. (2012). The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nature Medicine, 18, 1643\u20131650.","journal-title":"Nature Medicine"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-021-09639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-021-09639-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-021-09639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T10:45:42Z","timestamp":1671360342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-021-09639-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,21]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["9639"],"URL":"https:\/\/doi.org\/10.1007\/s12012-021-09639-0","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,21]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that there is no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}